A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
about
Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen valuesVerifying reference intervals for coagulation tests by using stored data.Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus.Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk.A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC StudyComparison of isoflurane and α-chloralose in an anesthetized swine model of acute pulmonary embolism producing right ventricular dysfunctionThrombophilia Associated with Anti-DFS70 Autoantibodies.Ethanol Extract of Persimmon Tree Leaves Improves Blood Circulation and Lipid Metabolism in Rats Fed a High-Fat DietNovel Dielectric Coagulometer Identifies Hypercoagulability in Patients with a High CHADS2 Score without Atrial Fibrillation.Venous thromboembolism: disease burden, outcomes and risk factors.Activated partial thromboplastin time and risk of future venous thromboembolism.A gene-centric analysis of activated partial thromboplastin time and activated protein C resistance using the HumanCVD focused genotyping array.New approaches in the measurement of coagulation.Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism.Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma.Using the laboratory to predict recurrent venous thrombosis.Lessons from genome-wide association studies in venous thrombosis.Current knowledge on the genetics of incident venous thrombosis.Short-term effect of dark chocolate consumption on routine haemostasis testing.Dynamic APTT parameters: applications in thrombophilia.Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients.Evidence for a Hypercoagulable State in Women With Ovarian Endometriomas.The use of dielectric blood coagulometry in the evaluation of coagulability in patients with peripheral arterial disease.Epidemiology of venous thromboembolism.Crotalus atrox venom preconditioning increases plasma fibrinogen and reduces perioperative hemorrhage in a rat model of surgical brain injury.Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors.Activated partial thromboplastin time (APTT). New indications for an old test?Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.Effects of remote ischemic preconditioning on the coagulation profile of patients with aneurysmal subarachnoid hemorrhage: a case-control study.Spontaneous cervical artery dissection is accompanied by a hypercoagulable state and simultaneous inflammatory condition.Retrospective evaluation of shortened prothrombin time or activated partial thromboplastin time for the diagnosis of hypercoagulability in dogs: 25 cases (2006-2011).Association of Admission Glucose Level and Improvement in Pulmonary Artery Pressure in Patients with Submassive-type Acute Pulmonary Embolism.Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena.Can haematological tests predict cardiovascular risk? The 2005 Kettle Lecture.An international study of how laboratories handle and evaluate patient samples after detecting an unexpected APTT prolongation.Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration.Novel measurements of blood coagulability for assessing the risk of thrombosis.Coronary Artery Disease Presentation and Its Association with Shortened Activated Partial Thromboplastin Time.Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal
P2860
Q28743200-10EBA00C-924B-4330-9E15-BE3FDA1E74CDQ34053651-D248FD6A-B149-4903-AD8B-5DABE8FA85AAQ34461796-653F3871-169A-42D0-A5C1-7330E400805FQ35025682-FDC58BD0-03C9-4B91-8BFA-057EB7F88FF7Q35221427-0F70C6B1-4FDB-4A40-B211-588288989BA1Q35415000-385E14F2-66F8-4FCA-A5F7-B520D69ED973Q35784744-F9D026FB-D1B9-44D7-A4AE-E359B0CC7700Q35821720-EC457B56-1906-499C-89C8-443474D89A69Q36044932-CC5110B7-A018-4B1F-B55B-C5B0860A5684Q36230821-A46E1ABA-C5F9-4141-9417-BD27CD2E910EQ36542496-AA38EEF6-318E-4EA1-952D-0303FD0CA147Q36929932-00E71295-8653-459F-8E9D-3FC485803EFAQ37176510-A66A9D7B-3D26-47C6-80C6-5A79CD2C1EBEQ37340732-55ADC68C-35A1-4716-AE8F-3784C407586BQ37406779-C36D8A60-7CFF-4B03-B10D-700C5F735CE9Q37892665-EB9DD94F-976C-42DD-8C1E-2964B0258C68Q37903948-655B810E-1787-4744-B869-FD4666DD287CQ38117729-4A2E19C9-6C3C-4ABF-B42A-36137C1E2FDDQ39101004-6625BEE8-B6BD-4F9A-9E14-A707D0FF0895Q40013023-4B8216A8-4A51-494C-BC6B-249EC685501EQ40315712-04D5CC78-DF01-4D98-9F04-BFB218C0F7CDQ41377815-79F46399-4646-4788-B8E5-243BD4F93F68Q41507499-D77BA23B-B7DA-4AC3-88FD-05D5AB1324C7Q41667853-C32884A4-58FA-48D3-BAD9-F19FF12A780EQ42097831-951240A1-A9DD-4EC8-8CA3-1C95E68B19EDQ45856680-C114D7C3-D7E2-483C-BAEF-4816FE798829Q45857730-450EE84D-ABB5-469F-80D7-7DE06D5BD9EDQ45866930-0FB1D25B-0767-4B92-A630-C5FA01C8F332Q46712145-6CEBE502-B01E-48AF-B8EE-B130538566B9Q47311457-ED1D6416-7A51-4013-9BDC-5CA1E96F7CD0Q47827350-55706ACC-B8AC-4CFB-AC9F-601AF31D0D65Q47963489-9FF08D1C-3FA6-44CB-87AA-011997B10299Q48259162-78F6D359-1AC5-4A03-B2ED-3103890BCC72Q48560063-5C19BAC1-6461-4234-90CB-A0BA46A9940AQ49048785-5ED304F7-9066-4617-B1C7-420FC18B870AQ50062366-E11136E7-2913-45D0-ACD1-B12F0F39639CQ50213067-9F93CE58-5596-4799-B858-FB6655E06101Q55619171-B9A1E704-A8F7-4080-B0FC-67D36A5E9DADQ56997786-E968AA7A-EBBD-4286-9DA0-F99172F3378B
P2860
A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
A shortened activated partial ...... isk of venous thromboembolism.
@en
A shortened activated partial ...... isk of venous thromboembolism.
@nl
type
label
A shortened activated partial ...... isk of venous thromboembolism.
@en
A shortened activated partial ...... isk of venous thromboembolism.
@nl
prefLabel
A shortened activated partial ...... isk of venous thromboembolism.
@en
A shortened activated partial ...... isk of venous thromboembolism.
@nl
P50
P1433
P1476
A shortened activated partial ...... isk of venous thromboembolism.
@en
P2093
Armando Tripodi
Veena Chantarangkul
P304
P356
10.1182/BLOOD-2004-03-1042
P407
P577
2004-08-05T00:00:00Z